Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant anthracycline + cyclophosphamide followed by nab-paclitaxel or docetaxel for breast cancer
ChiCTR1900027327Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, paclitaxel and docetaxel in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: 2-year disease-free survival. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
cyclophosphamidepaclitaxeldocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900027327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027327.